Mini-webinar: Can cystatin C eGFR improve accuracy in kidney care?

03. Jan 2024 | 4 min read

Mini-webinar: Can cystatin C eGFR improve accuracy in kidney care?

In the series of mini-webinars on cystatin C and kidney health our Global Product Manager for Cystatin C Mr. Gaute Tangen focuses on cystatin C eGFR as a potential enhancer of accuracy and reliability of estimating kidney function.

The biomarker cystatin C

Cystatin C is produced at a constant rate and freely filtered by the kidneys. The biomarker is less influenced by factors like age, gender or muscle mass compared to creatinine. Therefore, using cystatin C, combined with or instead of creatinine, might offer a more accurate estimations of kidney function, particularly in populations where testing with creatinine can be less reliable.

Research and studies conducted by the European Kidney Function Consortium (EKFC) and other groups have explored the utility of cystatin C as a biomarker for kidney function estimation without the inclusion of race and sex. By integrating cystatin C into the EKFC equation for estimating GFR, there's a potential for heightened accuracy.

Watch webinar: Can cystatin C eGFR improve accuracy in kidney care?

In this short webinar we will look into an article focusing on estimation of GFR without inclusion of race and sex that are published in The New England Journal of Medicine:
Cystatin C-Based Equation to Estimate GFR without the Inclusion of Race and Sex

 

 

Watch on YouTube

 

Cystatin C in European Kidney Function Consortium (EKFC) equation

The European Kidney Function Consortium (EKFC) developed the creatinine-based equation (EKFC eGFRcr) to estimate GFR in the early 2000s. The creatinine-based equation aimed to standardise the estimation of GFR by adjusting the serum creatinine level to account for variations related to age, sex, or race.

Resent research conducted across cohorts from Europe, the United States, and Africa demonstrates that the newly developed cystatin C-based equation (EKFC eGFRcys) shows improved accuracy in assessing GFR compared to commonly used equations. The advantage of this equation stemmed from cystatin C's properties as a biomarker less influenced by factors like age, sex, or muscle mass, making it potentially more reliable in estimating kidney function across diverse populations.

 

Contact Gentian - Cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing. Fill out the form below or send an email to marketing@gentian.com

 

Previous mini-webinars

 

Cystatin C, Creatinine and eGFR Equations

Disparities in kidney care

 

 

 

 

 

 

 

 

You may also read


FAQ: What role has circulating calprotectin in vasculitis?

Apr 17, 2024

FAQ: What role has circulating calprotectin in vasculitis?

Vasculitis and rheumatic diseases Vasculitis is a group of disorders characterised by inflammation of the..

Cystatin C testing - Balancing additional costs against potential benefits

Apr 11, 2024

Cystatin C testing - Balancing additional costs against potential benefits

The KDIGO (Kidney Disease: Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and..

Scientists to Gentian’s R&D department

Apr 08, 2024

Scientists to Gentian’s R&D department

Scientists to Gentian’s application validation group We are looking for two new colleagues in the positions..